Smith & Nephew plc (NYSE:SNN) Shares Sold by Deprince Race & Zollo Inc.

Deprince Race & Zollo Inc. lowered its holdings in Smith & Nephew plc (NYSE:SNN) by 0.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 545,579 shares of the medical equipment provider’s stock after selling 1,104 shares during the quarter. Deprince Race & Zollo Inc. owned 0.12% of Smith & Nephew worth $13,410,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the stock. Sei Investments Co. lifted its position in shares of Smith & Nephew by 229.8% during the 4th quarter. Sei Investments Co. now owns 75,215 shares of the medical equipment provider’s stock worth $1,849,000 after purchasing an additional 52,411 shares during the last quarter. Townsquare Capital LLC increased its holdings in shares of Smith & Nephew by 19.0% in the 4th quarter. Townsquare Capital LLC now owns 17,557 shares of the medical equipment provider’s stock valued at $432,000 after purchasing an additional 2,798 shares in the last quarter. Blue Trust Inc. raised its stake in shares of Smith & Nephew by 26.0% during the 4th quarter. Blue Trust Inc. now owns 5,871 shares of the medical equipment provider’s stock worth $144,000 after buying an additional 1,213 shares during the last quarter. ABC Arbitrage SA acquired a new position in shares of Smith & Nephew during the 4th quarter worth approximately $4,847,000. Finally, GAMMA Investing LLC raised its stake in Smith & Nephew by 31.8% in the 4th quarter. GAMMA Investing LLC now owns 2,975 shares of the medical equipment provider’s stock valued at $73,000 after purchasing an additional 718 shares during the last quarter. Hedge funds and other institutional investors own 25.64% of the company’s stock.

Smith & Nephew Stock Up 0.0 %

NYSE:SNN opened at $28.34 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.11 and a current ratio of 2.51. The company has a market cap of $12.41 billion, a price-to-earnings ratio of 13.12, a P/E/G ratio of 1.26 and a beta of 0.68. The stock’s fifty day moving average price is $27.59 and its two-hundred day moving average price is $26.30. Smith & Nephew plc has a 52-week low of $23.69 and a 52-week high of $31.72.

Smith & Nephew Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Friday, March 28th will be given a dividend of $0.447 per share. The ex-dividend date is Friday, March 28th. This represents a dividend yield of 2.5%. This is a positive change from Smith & Nephew’s previous semi-annual dividend of $0.29. Smith & Nephew’s dividend payout ratio (DPR) is currently 41.20%.

Analysts Set New Price Targets

Several equities research analysts have issued reports on SNN shares. StockNews.com upgraded shares of Smith & Nephew from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, February 26th. Canaccord Genuity Group increased their target price on Smith & Nephew from $27.00 to $28.00 and gave the stock a “hold” rating in a research report on Thursday, May 1st. Hsbc Global Res lowered shares of Smith & Nephew from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 25th. UBS Group cut Smith & Nephew from a “buy” rating to a “neutral” rating in a research note on Wednesday, March 12th. Finally, HSBC lowered Smith & Nephew from a “buy” rating to a “hold” rating in a report on Friday, April 25th. Six investment analysts have rated the stock with a hold rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $28.00.

Smith & Nephew Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.